Cargando...
Posttransplant chimeric antigen receptor therapy
Therapeutic T-cell engineering is emerging as a powerful approach to treat refractory hematological malignancies. Its most successful embodiment to date is based on the use of second-generation chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule found in most B-cell leukemias a...
Gardado en:
| Publicado en: | Blood |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Hematology
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5865610/ https://ncbi.nlm.nih.gov/pubmed/29358181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-08-752121 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|